Which antidepressant is contraindicated in pregnancy due to the risk of congenital defects?

Paroxetine is recognized as contraindicated in pregnancy primarily due to its association with an increased risk of congenital defects, particularly cardiac anomalies and other physical malformations. Studies have shown that the use of paroxetine during the first trimester is correlated with a significant risk of serious birth defects, prompting concerns about its safety profile for pregnant individuals.

In contrast, although other SSRIs and SNRIs may have some risks associated with them during pregnancy, fluoxetine and sertraline are generally considered to have a comparatively better safety profile. Duloxetine, while also an important medication, does not have the same level of established risk for congenital anomalies as paroxetine does. As a result, careful consideration must be given to medication choices for managing depression in pregnant individuals to minimize potential risks to the fetus.